The identified much smaller titin antigenic region should lead to easier antigen production and thus less expensive diagnostics, to lower non-specific binding, i.e., more specific diagnostics, and should facilitate research on the relation of anti-titin antibodies with thymoma and with MG induction. This evidence concerns the gene TTN and myasthenia gravis.